calystegine A3: also inhibits beta-xylosidase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 183073 |
| CHEMBL ID | 3233942 |
| SCHEMBL ID | 2441256 |
| MeSH ID | M0286617 |
| Synonym |
|---|
| calystegine a3 |
| 131580-36-4 |
| (+)-calystegine a3 |
| 8-azabicyclo(3.2.1)octane-1,2,3-triol, (1r,2s,3r,5r)- |
| CHEMBL3233942 , |
| SCHEMBL2441256 |
| bdbm50002856 |
| 8-azabicyclo[3.2.1]octane-1,2,3-triol |
| 8-azabicyclo[3.2.1]octane-1,2,3-triol, (1r,2s,3r,5r)- |
| (1r,2s,3r,5r)-8-azabicyclo[3.2.1]octane-1,2,3-triol |
| FS-6674 |
| AKOS040736012 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Lysosomal acid glucosylceramidase | Homo sapiens (human) | IC50 (µMol) | 16.0000 | 0.0300 | 2.3589 | 8.8000 | AID1125774 |
| Lysosomal acid glucosylceramidase | Homo sapiens (human) | Ki | 6.3000 | 0.0210 | 1.5288 | 6.3000 | AID1125775 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| galactosylceramidase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| glucosylceramidase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| signaling receptor binding | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| scavenger receptor binding | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| protein binding | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| glucosyltransferase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| steryl-beta-glucosidase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lysosome | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| lysosomal membrane | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| endoplasmic reticulum | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| Golgi apparatus | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| trans-Golgi network | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| lysosomal lumen | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| extracellular exosome | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1125773 | Stabilization of human lysosomal beta-glucocerebrosidase using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate assessed as remaining enzyme activity at 50 uM at 53 degC after 60 mins relative to control | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8 | Docking and SAR studies of calystegines: binding orientation and influence on pharmacological chaperone effects for Gaucher's disease. |
| AID1125775 | Competitive inhibition of human lysosomal beta-glucocerebrosidase using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate preincubated for 45 mins before substrate addition measured after 30 mins by double-reciprocal plot analysis | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8 | Docking and SAR studies of calystegines: binding orientation and influence on pharmacological chaperone effects for Gaucher's disease. |
| AID1125774 | Inhibition of human lysosomal beta-glucocerebrosidase using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate preincubated for 45 mins before substrate addition measured after 30 mins by fluorescence spectrophotometer analysis | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8 | Docking and SAR studies of calystegines: binding orientation and influence on pharmacological chaperone effects for Gaucher's disease. |
| AID1125777 | Increase of intracellular activity of beta-glucocerebrosidase in human N370S cells using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate at 250 uM after 4 days relative to control | 2014 | Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8 | Docking and SAR studies of calystegines: binding orientation and influence on pharmacological chaperone effects for Gaucher's disease. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||